Free Medical Fit Call
Patient Login

Hormone Therapy for Women in Denver: A Physician-Led Approach

By Kyle Kingsley, MD
Medical Director, LiteWell

Estimated Reading Time: 9 minutes

Denver women live at the intersection of ambition and altitude. Whether you’re summiting a fourteener before work, logging miles on the Cherry Creek Trail, or simply trying to keep up with a full life at 5,280 feet, your body is working harder than most people realize. When hormones begin to shift — as they inevitably do during perimenopause and menopause — the impact can be felt in ways that feel disproportionate to what your peers describe, because in many ways, they are. High altitude amplifies physiological stress, and declining estrogen compounds it.

Hormone therapy for women has undergone a significant reappraisal in the medical community over the past two decades. What was once dismissed or feared is now understood, through careful analysis of long-term data and updated clinical guidelines, to be a safe, effective, and often transformative option for appropriately selected women. The Menopause Society, the American College of Obstetricians and Gynecologists, and the Endocrine Society have all updated their positions to reflect this nuanced understanding.

This article covers what hormone therapy for women actually involves, how to know if you might benefit, what the research says, and how LiteWell’s physician-led approach in Denver delivers a comprehensive, individualized evaluation — not a one-size-fits-all prescription.

Key Takeaways

  • Hormone therapy (HRT/MHT) is the most effective treatment for vasomotor symptoms like hot flashes and night sweats, and is supported by major medical societies for appropriately selected women.
  • The “timing hypothesis” suggests that initiating therapy within 10 years of menopause onset or before age 60 offers the most favorable risk-benefit profile.
  • Perimenopausal hormone changes affect not just reproductive function but also cognition, mood, sleep, bone density, cardiovascular health, and metabolic function.
  • Transdermal estrogen (patch, gel, spray) avoids first-pass liver metabolism and may carry a more favorable clot risk profile compared to oral estrogen.
  • A thorough evaluation — including comprehensive labs, clinical history, and individualized risk assessment — is essential before initiating hormone therapy.
  • LiteWell’s physician-led model goes beyond symptom management, integrating hormones into a broader optimization strategy that includes nutrition, resistance training, and sleep.
  • Compounded hormones differ from FDA-approved formulations and carry distinct considerations that should be discussed with a physician.

Table of Contents

  1. What Is Hormone Therapy for Women?
  2. The Hormonal Shift: What’s Happening in Your Body
  3. Signs You May Benefit from Hormone Therapy
  4. Diagnosis and Evaluation: How LiteWell Assesses HRT Candidacy
  5. What the Research Shows: Evidence-Based HRT
  6. Myths vs. Facts About Hormone Therapy
  7. LiteWell’s Clinical Approach to Hormone Therapy in Denver
  8. Frequently Asked Questions
  9. Related LiteWell Services
  10. References

What Is Hormone Therapy for Women?

Hormone therapy for women — referred to interchangeably as hormone replacement therapy (HRT) or menopausal hormone therapy (MHT) — involves the administration of hormones to supplement declining or deficient levels in the body. The primary hormones involved are estrogen, progesterone (or the synthetic progestin), and, increasingly, testosterone.

Estrogen is the cornerstone of most hormone therapy regimens. It is responsible for regulating the menstrual cycle, maintaining vaginal tissue health, supporting bone density, influencing mood and cognition, and modulating cardiovascular function. During menopause, estrogen production from the ovaries drops dramatically, triggering the cascade of symptoms most women associate with “the change.”

Progesterone (or a progestin) is typically added for women who still have a uterus, to protect the uterine lining from the proliferative effects of unopposed estrogen. Micronized progesterone — bioidentical in structure to the body’s own progesterone — is now widely preferred over synthetic progestins due to a more favorable side effect profile and emerging data suggesting better tolerability.

Testosterone is often overlooked in conversations about women’s hormones, yet it plays an important role in libido, energy, muscle maintenance, cognitive sharpness, and overall sense of well-being. Levels decline steadily through the reproductive years, and the drop can be particularly noticeable during and after menopause. While testosterone therapy for women is used off-label in the United States, it is supported by clinical evidence and endorsed by the International Society for the Study of Women’s Sexual Health (ISSWSH).

Hormone therapy is available in multiple delivery formats, each with distinct pharmacokinetic profiles: oral tablets, transdermal patches, topical gels or creams, sprays, vaginal rings, pellets, and injections. The choice of delivery method depends on individual health history, preferences, convenience, and clinical goals. This is not a decision that should be made in a vacuum — it requires physician-led evaluation and ongoing monitoring.

The Hormonal Shift: What’s Happening in Your Body

The transition from regular menstrual cycles to menopause is rarely a clean handoff. Perimenopause — the transitional phase leading up to menopause — can begin as early as the late 30s and extend for a decade or more. During this time, the ovaries gradually produce less estrogen and progesterone, but not in a smooth, linear decline. The fluctuations are erratic. Estrogen can surge to abnormally high levels before plummeting, creating a hormonal environment that is chaotic, not simply “low.”

At the center of this system is the hypothalamic-pituitary-ovarian (HPO) axis. The hypothalamus signals the pituitary gland to release follicle-stimulating hormone (FSH), which in turn tells the ovaries to produce estrogen. As the ovaries become less responsive, FSH rises — sometimes dramatically — in an attempt to elicit a response that is no longer forthcoming. Elevated FSH is one of the clinical markers used to assess menopausal status, though it must be interpreted carefully during perimenopause when levels fluctuate significantly.

Estrogen receptors are found throughout the body — not just in the reproductive organs. They exist in the brain, heart, bones, skin, bladder, gut, and blood vessels. This is why declining estrogen has such far-reaching effects. Hot flashes originate in the brain’s thermoregulatory center. Bone loss accelerates because estrogen normally suppresses osteoclast activity. Cardiovascular risk begins to rise. Vaginal and urinary tissues thin and lose elasticity — a condition known as genitourinary syndrome of menopause (GSM).

For active Denver women, this physiological picture matters in concrete terms. At altitude, the cardiovascular and respiratory systems are already working harder. Reduced aerobic efficiency from declining estrogen — combined with disrupted sleep from night sweats — can translate into noticeably reduced endurance on the trail or the slopes. Women who have spent years building athletic capacity can find that their performance drops in ways that feel unexplained and frustrating, when in fact the hormonal picture tells the story clearly.

Testosterone, meanwhile, has been declining since the mid-30s. By the time a woman reaches menopause, testosterone levels may be half of what they were at peak. This contributes to reduced muscle mass and strength, decreased motivation and drive, and diminished libido — all compounded by the ovarian hormones dropping simultaneously.

Signs You May Benefit from Hormone Therapy

Hormone therapy is not right for every woman, and the decision to pursue it must be individualized. That said, certain symptom patterns suggest that hormonal changes are significantly impacting quality of life and that evaluation is warranted.

Vasomotor Symptoms: Hot Flashes and Night Sweats

Hot flashes and night sweats — collectively called vasomotor symptoms (VMS) — are the hallmark of the menopausal transition. They occur when the brain’s thermostat, the hypothalamus, becomes hypersensitive to small changes in core body temperature due to estrogen withdrawal. The result: a sudden, intense sensation of heat, often accompanied by flushing, sweating, and a rapid heartbeat that can last from seconds to several minutes.

VMS affect up to 80% of women during the menopausal transition. For some, they are mild and infrequent. For others — particularly those with frequent, severe episodes — they severely disrupt daily functioning. Hormone therapy, specifically estrogen, remains the most effective available treatment for VMS, with clinical trials consistently demonstrating 75–90% reduction in frequency and severity. Non-hormonal options exist but are generally less effective.

Sleep Disruption

Sleep disruption during the menopausal transition is multifactorial. Night sweats are a primary driver, but estrogen and progesterone also directly influence sleep architecture independent of temperature dysregulation. Estrogen affects serotonin and norepinephrine pathways involved in sleep regulation, while progesterone has a mild sedative quality via GABA-A receptor interaction.

Poor sleep has downstream consequences that go well beyond fatigue. Cognitive performance suffers. Cortisol dysregulation worsens. Insulin sensitivity declines. Mood is destabilized. For a Denver woman managing a career, family, and an active lifestyle, sleep disruption is not a minor inconvenience — it erodes the foundation everything else rests on. Restoring hormonal balance can meaningfully improve sleep quality, particularly when progesterone is included in the regimen.

Brain Fog and Cognitive Changes

Many women describe a distinct change in cognitive sharpness during perimenopause: difficulty finding words, trouble concentrating, reduced ability to multitask, or a sense that their mental processing has slowed. This is not imagined. Estrogen supports neuronal function, promotes synaptic plasticity, and modulates acetylcholine and dopamine systems critical to memory and executive function.

The Study of Women’s Health Across the Nation (SWAN) documented cognitive changes during perimenopause, with some recovery after the menopause transition stabilizes. Whether hormone therapy provides long-term cognitive benefit — particularly for dementia risk — remains an active area of research, with the timing hypothesis appearing relevant here as well. What is well-established is that addressing the sleep disruption and vasomotor burden that accompanies the transition tends to improve cognitive symptoms meaningfully.

Mood, Anxiety, and Emotional Changes

The perimenopausal period carries a significantly elevated risk of depression and anxiety, even in women with no prior psychiatric history. Estrogen modulates serotonin reuptake and receptor sensitivity, and progesterone metabolites interact with GABA receptors — the same systems targeted by many psychiatric medications. As these hormones fluctuate erratically, mood regulation becomes harder.

Women may experience irritability, emotional lability, a sense of dread, or a loss of the resilience they once took for granted. These symptoms are often mistakenly attributed purely to life stress or treated with antidepressants before a hormonal evaluation is completed. A physician-led approach ensures the hormonal dimension is assessed before or alongside other interventions, particularly in women whose mood changes correlate with hormonal fluctuation patterns.

Diagnosis and Evaluation: How LiteWell Assesses HRT Candidacy

A thoughtful hormone evaluation is not simply ordering an estrogen level. This is one of the most common limitations of conventional care: a single blood draw during perimenopause, when estrogen fluctuates dramatically day to day, provides limited actionable information. A comprehensive evaluation requires clinical context, symptom history, and a panel of relevant biomarkers interpreted in their proper relationship to one another.

At LiteWell, the evaluation begins with a detailed symptom inventory and medical history. This includes menstrual cycle history, prior pregnancies and contraceptive use, personal and family history of hormone-sensitive cancers, cardiovascular history, bone health considerations, and current medications. The clinical picture shapes how lab results are interpreted.

Laboratory evaluation typically includes estradiol (E2), FSH, progesterone, total and free testosterone, SHBG (sex hormone-binding globulin), DHEA-S, thyroid panel (TSH, free T3, free T4), complete metabolic panel, lipid panel, and CBC. SHBG is particularly important because it determines how much testosterone is biologically active — high SHBG, which is common with oral estrogen use, can significantly reduce free testosterone availability.

Timing of lab work matters. For women who are still cycling, hormone panels are ideally drawn on specific cycle days to capture meaningful progesterone levels. For women who are postmenopausal, timing is less critical, but the context of any current hormone use must be accounted for. The goal is not to hit a number on a reference range — it is to understand the hormonal environment in the context of the individual’s symptoms, history, and goals.

Risk stratification is an essential component of evaluation. Contraindications to hormone therapy — including certain types of breast cancer, unexplained vaginal bleeding, active thromboembolic disease, and specific cardiovascular conditions — must be systematically assessed. For women with more complex histories, a nuanced risk-benefit discussion is required, not a blanket exclusion.

What the Research Shows: Evidence-Based HRT

The evidence base for hormone therapy has evolved substantially since the Women’s Health Initiative (WHI) trial results were published in 2002 and 2003. The initial reports triggered a dramatic reduction in hormone therapy prescribing — a reaction that subsequent analysis has shown was not fully warranted, particularly for the population most likely to benefit.

The Menopause Society (formerly NAMS) issued a comprehensive position statement in 2022 affirming that hormone therapy remains the most effective treatment for vasomotor symptoms and GSM, and that for healthy women under 60 or within 10 years of menopause, the benefits generally outweigh the risks. This position is echoed by the Endocrine Society and the American College of Obstetricians and Gynecologists (ACOG).

The timing hypothesis — also called the “window of opportunity” — refers to the observation that initiating hormone therapy early in the menopausal transition (within 10 years of menopause or before age 60) is associated with more favorable cardiovascular and potentially cognitive outcomes compared to initiating later. The WHI population skewed significantly older, which contributed to the risk signals that were initially over-generalized to all menopausal women.

Bone health is a well-established benefit of estrogen therapy. Estrogen inhibits osteoclast-mediated bone resorption, and its decline after menopause is the primary driver of the accelerated bone loss that places postmenopausal women at elevated risk for osteoporosis and fragility fractures. The FDA has approved estrogen therapy for prevention of postmenopausal osteoporosis.

Route of administration matters clinically. Transdermal estrogen — delivered via patch, gel, or spray — bypasses first-pass hepatic metabolism, resulting in a different metabolite profile than oral estrogen. Clinical data, including the E3N cohort study, suggests that transdermal estrogen combined with micronized progesterone may carry a lower thromboembolic and breast cancer risk compared to oral estrogen with synthetic progestins. These distinctions inform LiteWell’s prescribing approach.

FDA-approved versus compounded hormones is a distinction that deserves physician-level discussion. FDA-approved bioidentical hormones — estradiol patches, gels, and micronized progesterone — are manufactured under controlled conditions with established purity, potency, and safety data. Compounded hormones offer flexibility in dosing and delivery but are not FDA-approved and lack equivalent safety surveillance. The clinical decision between them should be individualized, transparent, and informed.

Myths vs. Facts About Hormone Therapy

Myth: Hormone therapy always causes breast cancer.

Fact: The relationship between hormone therapy and breast cancer risk is nuanced and depends on the type of hormone, route of administration, duration of use, and individual risk factors. For many women, particularly those using transdermal estrogen with micronized progesterone, the absolute risk increase — if any — is small. Major medical societies do not categorically contraindicate hormone therapy for women with average breast cancer risk.

Myth: You should stop hormone therapy as soon as possible.

Fact: There is no universal time limit on hormone therapy. Duration of use is individualized. Annual reassessment of risks and benefits is recommended, but many women use hormone therapy safely for extended periods under physician supervision.

Myth: Natural menopause means you should suffer through it.

Fact: Menopause is natural; so is treating its symptoms. We routinely treat other natural physiological changes — hypothyroidism, insulin resistance, vitamin deficiencies — without suggesting patients simply endure them. Hormone therapy is evidence-based medicine, not an intervention against nature.

Myth: Hormone therapy causes weight gain.

Fact: Weight gain around menopause is primarily driven by metabolic changes, reduced physical activity, and the loss of estrogen’s favorable effects on body composition — not by hormone therapy itself. Some data suggests that estrogen therapy may actually attenuate menopausal weight gain and preserve lean mass when combined with resistance training and appropriate nutrition.

Myth: You can’t use hormone therapy if you have a family history of breast cancer.

Fact: Family history requires careful evaluation, not automatic exclusion. A physician-led risk assessment — including assessment of genetic risk, relative risk magnitude, and the severity of menopausal symptoms — is required to make an individualized, informed decision.

Myth: Bioidentical hormones from a compounding pharmacy are always safer than FDA-approved options.

Fact: “Bioidentical” refers to molecular structure, not safety or regulatory status. FDA-approved bioidentical estradiol and micronized progesterone are available and well-studied. Compounded preparations are not inherently safer and lack the same manufacturing quality controls and post-market surveillance.

LiteWell’s Clinical Approach to Hormone Therapy in Denver

LiteWell is a physician-led, cash-pay medical practice built around the principle that optimal health requires comprehensive evaluation, not reactive treatment. For women considering hormone therapy, this means starting with a thorough understanding of who you are — your symptoms, your labs, your history, your goals — before making any prescribing decisions.

The entry point for new patients is a Free Medical Fit Call, a brief consultation to ensure LiteWell’s model is the right fit. For those who move forward, the Premier Discovery Intake is a deep-dive evaluation that gives the clinical team the full picture needed to develop a personalized hormone strategy.

LiteWell is not in the business of issuing quick prescriptions. The standard of care here is comprehensive: labs drawn and interpreted in clinical context, a detailed symptom and history review, individualized risk stratification, and an honest conversation about options — including FDA-approved therapies, compounded options where appropriate, and the evidence behind each choice. Follow-up monitoring is structured, not an afterthought.

For women in Colorado, the Denver clinic at 3000 E 1st Ave Suite 114, Denver CO 80206 provides in-person care. LiteWell also offers a hybrid care model — combining in-clinic visits with remote follow-up — so women across the state can maintain continuity without sacrificing the quality of physician oversight.

Denver attracts women who are high-performers — professionals, athletes, outdoor enthusiasts — who notice when their body isn’t working the way it should. Hormones are rarely the only variable. LiteWell integrates hormone therapy into a broader optimization framework that includes resistance training programming, nutritional strategy, sleep hygiene, and stress physiology. For the woman skiing Breckenridge on the weekends and running a business during the week, that integration matters.

The goal is not simply to eliminate symptoms. It’s to help you function at the level you’ve built your life around — at altitude, at pace, for the long term.

Frequently Asked Questions

What is hormone therapy for women, and who is it for?

Hormone therapy for women (HRT or MHT) is the use of estrogen, progesterone, and sometimes testosterone to supplement declining hormone levels during perimenopause and menopause. It is primarily indicated for women experiencing significant vasomotor symptoms (hot flashes, night sweats), sleep disruption, genitourinary changes, mood instability, or bone loss related to hormonal decline. Candidacy is determined through a physician-led evaluation that includes medical history, symptom assessment, and comprehensive laboratory testing. It is not appropriate for all women — contraindications include certain cancers, active clotting disorders, and specific cardiovascular conditions.

What are the main benefits of hormone therapy?

The most well-established benefit is relief from vasomotor symptoms — estrogen therapy reduces hot flash frequency and severity by 75–90% in clinical trials. Other documented benefits include improved sleep quality, relief from genitourinary syndrome of menopause (GSM), preservation of bone density, improved mood and cognitive function, and for some women, maintained libido and sexual function when testosterone is included. Emerging evidence also supports cardiovascular benefits when therapy is initiated within the “window of opportunity” — within 10 years of menopause or before age 60.

Does hormone therapy increase breast cancer risk?

The relationship is nuanced and depends on the type and route of hormones used. The combination of oral estrogen and synthetic progestins used in the original Women’s Health Initiative showed a modest increase in breast cancer risk with extended use. However, evidence suggests that transdermal estrogen combined with micronized progesterone carries a different — and potentially more favorable — risk profile. The absolute risk increase for most women is small, and the clinical decision must weigh individual risk factors, symptom severity, and quality of life. Major medical societies do not categorically advise against hormone therapy for women with average breast cancer risk.

What is the difference between estrogen-only and combined hormone therapy?

Estrogen-only therapy is appropriate for women who have had a hysterectomy and no longer have a uterus. For women with an intact uterus, estrogen must be combined with progesterone (or a progestin) to protect the uterine lining from endometrial hyperplasia and cancer risk associated with unopposed estrogen. The type of progesterone matters: micronized progesterone (bioidentical) is generally preferred over synthetic progestins due to better tolerability and a more favorable safety profile based on available data.

What is transdermal hormone therapy, and is it better than oral?

Transdermal estrogen is delivered through the skin via patches, gels, or sprays, bypassing first-pass liver metabolism. This results in a different metabolite profile than oral estrogen and may be associated with lower risk of blood clots (venous thromboembolism) and potentially lower impact on triglycerides and clotting factors. For women with cardiovascular risk factors or a history of clotting, transdermal delivery is often clinically preferred. Both forms are effective for symptom relief — the route choice is individualized based on health history, risk profile, and patient preference.

How long can I stay on hormone therapy?

There is no universal time limit. The old guidance to use “the lowest dose for the shortest time” has been updated by major medical societies to reflect a more individualized approach. Annual reassessment of risks, benefits, symptom status, and health changes is recommended — not arbitrary discontinuation. Many women use hormone therapy for extended periods safely under physician monitoring. The decision to continue, reduce, or stop therapy should be made collaboratively with a physician who knows your history and current health status.

Will hormone therapy cause me to gain weight?

No — hormone therapy is not associated with weight gain in well-controlled studies. The weight gain many women experience around menopause is driven by hormonal changes themselves (particularly declining estrogen’s effects on fat distribution and insulin sensitivity), reduced physical activity, and metabolic shifts — not by hormone therapy. Some research suggests estrogen therapy may attenuate menopausal changes in body composition and help preserve lean muscle mass, particularly when paired with resistance training and appropriate nutrition.

At what age can I start hormone therapy, and is there an age cutoff?

Most clinical guidelines support initiating hormone therapy for symptomatic women during the perimenopausal or early postmenopausal period, typically before age 60 or within 10 years of menopause — the “window of opportunity” associated with the most favorable risk-benefit profile. There is no strict minimum age; hormone therapy may be appropriate for women experiencing premature ovarian insufficiency (POI) as young as their 20s or 30s. For women initiating therapy later — over age 60 or more than 10 years post-menopause — a more cautious approach and detailed risk assessment are warranted.

What should I expect from my first appointment at LiteWell Denver?

New patients typically begin with a Free Medical Fit Call to ensure LiteWell’s model aligns with their goals. Those who move forward complete the Premier Discovery Intake — a comprehensive evaluation including detailed medical and hormone history, symptom review, and a laboratory panel that assesses estrogen, progesterone, testosterone, thyroid function, metabolic markers, and more. Based on this full picture, the LiteWell clinical team develops an individualized treatment plan. The Denver clinic at 3000 E 1st Ave Suite 114 also supports a hybrid care model for ongoing follow-up. You can reach the Denver office at +1-720-782-8935.

Are compounded hormones better than FDA-approved hormones?

Not necessarily — and the distinction deserves a candid physician-led conversation. FDA-approved bioidentical hormones, including estradiol patches, gels, and micronized progesterone, are manufactured under stringent quality controls and have established safety and efficacy data. Compounded hormones offer flexibility in dosing and delivery but lack FDA approval and equivalent regulatory oversight. “Bioidentical” refers to molecular structure, not safety status. Compounded preparations may be appropriate in specific clinical situations — such as when a patient needs a dose or delivery form not commercially available — but should not be assumed to be inherently safer or more effective.

Related LiteWell Services

Related Insights

  • Testosterone Therapy for Men: What to Know Before You Start
  • Understanding Perimenopause: The Decade Before Menopause That Changes Everything
  • Thyroid Health and Hormones: Why They’re Inseparable
  • Sleep, Cortisol, and Hormone Optimization: The Missing Piece
  • Medical Weight Loss for Women: Hormones, Metabolism, and GLP-1 Therapy

References

  • The Menopause Society (formerly NAMS). 2022 Hormone Therapy Position Statement.
  • American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin on Menopausal Hormone Therapy.
  • Endocrine Society. Clinical Practice Guideline: Treatment of Menopause.
  • Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. 2008.
  • Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative. JAMA. 2002.
  • International Society for the Study of Women’s Sexual Health (ISSWSH). Position Statement on Testosterone Therapy for Women.
  • Study of Women’s Health Across the Nation (SWAN). Cognitive function during menopausal transition.
  • U.S. Food and Drug Administration (FDA). Postmenopausal osteoporosis: approved uses of hormone therapy.
  • Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative randomized trials. JAMA. 2017.
  • National Institutes of Health (NIH). National Institute on Aging. Menopause and hormone therapy fact sheets.

Medical Disclaimer
This article is intended for educational purposes only and should not be interpreted as personalized medical advice. Medical decisions should be made in consultation with a licensed healthcare professional who is familiar with your medical history. Treatment plans are individualized, and results vary. LiteWell does not provide emergency medical care.

Medication & Regulatory Disclosure
Hormone therapies described in this article are prescription medications that require evaluation and authorization by a licensed physician. Some therapies discussed — including testosterone therapy for women and certain compounded formulations — are prescribed off-label and are not FDA-approved for all indications described. FDA-approved hormone therapies are available and are the preferred option in most clinical scenarios. Compounded medications are not FDA-approved and are prepared by state-licensed compounding pharmacies. Individual treatment decisions, including the choice between FDA-approved and compounded preparations, are made at the discretion of the treating physician based on each patient’s clinical profile. LiteWell does not guarantee specific outcomes. Results vary by individual.

Latest Articles